Page 64 - NobleCon21

Health Care
Date November 20, 2025 Health Care
52wk High $3.26
52wk Low $0.98 Cocrystal Pharma, Inc. COCP $0.97
19805 North Creek Parkway
Bothell, WA 98011

(USD - in millions) www.cocrystalpharma.com
Market Cap 12.9
Enterprise 6.8
Basic Shares Out. 13.04 COMPANY OVERVIEW
Float 8.61
Institutional Holdings 5.10% Detailed Analysis:Channelchek.com
Short Interest 0.26
Avg. 90-Day Volume 1.50 Cocrystal Pharma, Inc. is a clinical-stage biotechnology company
discovering and developing novel antiviral therapeutics that target the
replication process of influenza viruses, coronaviruses (including SARS-
CoV-2), noroviruses and hepatitis C viruses. Cocrystal employs unique
EPS Data structure-based technologies and Nobel Prize-winning expertise to
create first- and best-in-class antiviral drugs.
2022 2023 2024
CQ1 (0.48) (0.64) (0.39)
CQ2 (0.46) (0.50) (0.53)

CQ3 (0.70) (0.41) (0.49)
CQ4 (0.54) (0.54) (0.32)
CY (2.23) (2.13) (1.72) Source: Channelchek/QuoteMedia

Long-Term EPS Estimate N/A
Price/Book (mrq) 0.59
ROE (ttm) -94.94
Debt-to-Total Cap. (mrq) 17.11
Fiscal Year End 31-Dec

19805 North CBothell WA 98011

Key Executives
CEO: N/A
CFO: Martin, James
COO: N/A
IR: N/A
Noble Capital Markets, Inc.
Source: Capital IQ, Noble Financial estimates, company filings
Noble Senior Analyst 561-994-1191 noblecapitalmarkets.com
Robert LeBoyer MEMBERS: FINRA, SIPC, MSRB
rleboyer@noblelsp.com Following the conference, complete video library of presentations will be
available at: channelchek.com | nobleconference.com
(212) 896-4625

Refer to the back of the book for disclosures